文献速递银屑病与炎症性皮肤病

钙泊三醇联合二丙酸倍他米松气雾泡沫与阿普司特、甲氨蝶呤、阿维A或富马酸酯类治疗斑块状银屑病的匹配调整间接比较

Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-03-19

本研究将四项钙泊三醇/二丙酸倍他米松(Cal/BD)气雾泡沫试验中749例银屑病患者的个体数据汇总,与文献中阿普司特、甲氨蝶呤、阿维A或富马酸酯类(FAE)试验的聚合数据行匹配调整间接比较。结果示Cal/BD泡沫4周在PGA 0/1和PASI 75应答上优于阿普司特16周、甲氨蝶呤12周和阿维A12周,与FAE疗效相当。

要点

  • Cal/BD泡沫4周PGA 0/1应答52.7%,高于阿普司特16周的30.4%(P<0.001)。
  • Cal/BD泡沫4周PASI 75应答51.1%,高于阿普司特16周的21.6%(P<0.001)。
  • Cal/BD泡沫4周PASI 75应答与FAE相当(42.4% vs 47.0%,P=0.451)。

核心结论

  • 在基线匹配的银屑病患者中,Cal/BD泡沫的疗效优于阿普司特、甲氨蝶呤或阿维A,与FAE相当。
  • 尽管近期治疗有进展,银屑病患者仍存在未满足的需求。

研究设计与样本

  • 匹配调整间接比较,汇总四项Cal/BD泡沫试验共749例银屑病患者的个体数据。
  • 文献复习筛选出四项非生物制剂系统治疗试验,涉及阿普司特、甲氨蝶呤、阿维A或富马酸酯类(FAE)。
  • 从3090篇筛选文献中纳入四项研究。

主要发现

  • 基线匹配后,Cal/BD泡沫4周PGA 0/1应答为52.7%,阿普司特16周为30.4%(P<0.001)。
  • Cal/BD泡沫4周PASI 75应答为51.1%,阿普司特16周为21.6%(P<0.001)。
  • Cal/BD泡沫4周PASI 75应答为50.8%,甲氨蝶呤12周为33.5%(P<0.001)。
  • Cal/BD泡沫4周PASI 75应答为50.9%,阿维A12周为31.7%(P=0.009)。
  • Cal/BD泡沫4周PASI 75应答为42.4%,FAE为47.0%(P=0.451)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plaque psoriasis has significant impact on patients' quality of life. Topical therapy is considered the treatment mainstay for mild-to-moderate disease according to guidelines. Calcipotriol/betamethasone dipropionate (Cal/BD) [0.005%/0.05%] aerosol foam is indicated for psoriasis vulgaris treatment in adults. Cal/BD foam trials demonstrated improved efficacy and similar safety in this population. Psoriasis treatment is complicated by the broad range of disease presentation, variability and therapeutic options; particularly decisions on transition from topical to non-biologic systemic treatment are difficult. Assessing comparative effectiveness of treatment options provides meaningful value to treatment decisions. OBJECTIVE: To compare efficacy of Cal/BD foam individual patient data from pooled trials with efficacy of non-biologic systemic treatments based on aggregated patient characteristics and treatment outcomes. METHODS: Individual data from four Cal/BD foam trials in 749 psoriasis patients were pooled to conduct matching-adjusted indirect comparisons. Literature review identified non-biologic systemic treatment trials where methods, populations and outcomes align with Cal/BD foam trials. Of 3090 screened publications, four studies of apremilast, methotrexate, acitretin or fumaric acid esters (FAE) were included. RESULTS: After baseline matching, patients treated with 4 weeks of Cal/BD foam had greater Physician's Global Assessment 0/1 response compared to those treated with 16 weeks of apremilast (52.7% vs. 30.4%; P < 0.001). Patients treated with Cal/BD foam had significantly greater Psoriasis Area and Severity Index (PASI) 75 response at Week 4 compared to 16 weeks of apremilast treatment (51.1% vs. 21.6%; P < 0.001). Cal/BD foam patients demonstrated significantly greater PASI 75 response improvements at Week 4 vs. 12 weeks of methotrexate (50.8% vs. 33.5%; P < 0.001) or acitretin (50.9% vs. 31.7%; P = 0.009), and comparable response to FAE (42.4% vs. 47.0%; P = 0.451). CONCLUSIONS: Despite recent treatment advances, unmet needs for psoriasis patients remain. Cal/BD foam offers improved efficacy in baseline matched psoriasis patients compared to apremilast, methotrexate or acitretin, and comparable efficacy to FAE.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Bewley AP, Shear NH, Calzavara-Pinton PG, et al. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison. J Eur Acad Dermatol Venereol. 2019. PMID: 30472749. doi:10.1111/jdv.15369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。